Hutchison Medipharma Starts Clinical Trial on Fourth Cancer Drug

Published: Nov 02, 2012

November 2, 2012 -- Hutchison MediPharma, the drug discovery arm of China MediTech, has begun a Phase I clinical trial of Theliatinib (HMPL-309) in patients with non-small cell lung cancer. The drug is a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase. Unlike most EGFR inhibitors, Theliatinib has shown efficacy against NSCLC that does not display EGFR-enabling mutations in pre-clinical testing, according to Chi-Med. More details....

Back to news